Nevro Past Earnings Performance
Past criteria checks 0/6
Nevro has been growing earnings at an average annual rate of 11.2%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 2.9% per year.
Key information
11.2%
Earnings growth rate
14.6%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 2.9% |
| Return on equity | -25.3% |
| Net Margin | -16.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding
Aug 11
Nevro: Not Having My Back
Aug 09Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Jul 16Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
May 01Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Feb 25There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding
Jan 08Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Nov 16Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold
Sep 01Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?
Jul 10Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings
Feb 28Nevro falls to 52-week low; down ~49% over last year
Feb 22Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains
Feb 14Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Jan 13Nevro: Opportunity Overshadowed By Weaknesses
Dec 07Boston Scientific drives rival Nevro lower after remarks on neuromodulation
Oct 26Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval
Oct 13Nevro gets FDA approval for Costa Rica manufacturing operations
Oct 04Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Oct 02Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation
Sep 07Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Jun 17Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery
Jun 10Revenue & Expenses Breakdown
How Nevro makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 419 | -69 | 314 | 52 |
| 30 Jun 24 | 426 | -77 | 327 | 55 |
| 31 Mar 24 | 431 | -83 | 337 | 54 |
| 31 Dec 23 | 425 | -92 | 335 | 54 |
| 30 Sep 23 | 423 | -102 | 335 | 56 |
| 30 Jun 23 | 419 | 3 | 332 | 56 |
| 31 Mar 23 | 415 | 2 | 329 | 55 |
| 31 Dec 22 | 406 | 3 | 322 | 53 |
| 30 Sep 22 | 395 | -8 | 324 | 52 |
| 30 Jun 22 | 388 | -140 | 325 | 49 |
| 31 Mar 22 | 386 | -136 | 315 | 49 |
| 31 Dec 21 | 387 | -131 | 309 | 48 |
| 30 Sep 21 | 394 | -108 | 294 | 47 |
| 30 Jun 21 | 409 | -68 | 283 | 46 |
| 31 Mar 21 | 363 | -88 | 269 | 45 |
| 31 Dec 20 | 362 | -83 | 267 | 46 |
| 30 Sep 20 | 367 | -90 | 276 | 51 |
| 30 Jun 20 | 358 | -98 | 280 | 53 |
| 31 Mar 20 | 396 | -84 | 296 | 57 |
| 31 Dec 19 | 390 | -104 | 306 | 59 |
| 30 Sep 19 | 384 | -100 | 301 | 56 |
| 30 Jun 19 | 379 | -93 | 292 | 55 |
| 31 Mar 19 | 382 | -76 | 281 | 52 |
| 31 Dec 18 | 387 | -49 | 267 | 48 |
| 30 Sep 18 | 377 | -44 | 239 | 45 |
| 30 Jun 18 | 364 | -39 | 228 | 42 |
| 31 Mar 18 | 346 | -40 | 218 | 40 |
| 31 Dec 17 | 327 | -37 | 220 | 38 |
| 30 Sep 17 | 299 | -42 | 202 | 39 |
| 30 Jun 17 | 278 | -40 | 184 | 37 |
| 31 Mar 17 | 255 | -37 | 165 | 36 |
| 31 Dec 16 | 229 | -32 | 142 | 34 |
| 30 Sep 16 | 191 | -36 | 126 | 28 |
| 30 Jun 16 | 146 | -52 | 112 | 26 |
| 31 Mar 16 | 102 | -63 | 98 | 23 |
| 31 Dec 15 | 70 | -67 | 82 | 21 |
| 30 Sep 15 | 46 | -62 | 64 | 20 |
| 30 Jun 15 | 39 | -50 | 49 | 20 |
| 31 Mar 15 | 36 | -38 | 37 | 20 |
| 31 Dec 14 | 33 | -31 | 30 | 20 |
| 30 Sep 14 | 29 | -29 | 26 | 20 |
| 30 Jun 14 | 27 | -26 | 24 | 19 |
| 31 Mar 14 | 25 | -26 | 21 | 19 |
| 31 Dec 13 | 24 | -26 | 19 | 20 |
Quality Earnings: NVRO is currently unprofitable.
Growing Profit Margin: NVRO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NVRO is unprofitable, but has reduced losses over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare NVRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVRO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.4%).
Return on Equity
High ROE: NVRO has a negative Return on Equity (-25.33%), as it is currently unprofitable.